Tomoko Iwata

3.4k total citations · 1 hit paper
57 papers, 2.5k citations indexed

About

Tomoko Iwata is a scholar working on Molecular Biology, Cardiology and Cardiovascular Medicine and Endocrinology, Diabetes and Metabolism. According to data from OpenAlex, Tomoko Iwata has authored 57 papers receiving a total of 2.5k indexed citations (citations by other indexed papers that have themselves been cited), including 32 papers in Molecular Biology, 18 papers in Cardiology and Cardiovascular Medicine and 15 papers in Endocrinology, Diabetes and Metabolism. Recurrent topics in Tomoko Iwata's work include Fibroblast Growth Factor Research (14 papers), Diabetes Treatment and Management (14 papers) and Heart Failure Treatment and Management (12 papers). Tomoko Iwata is often cited by papers focused on Fibroblast Growth Factor Research (14 papers), Diabetes Treatment and Management (14 papers) and Heart Failure Treatment and Management (12 papers). Tomoko Iwata collaborates with scholars based in United Kingdom, United States and Japan. Tomoko Iwata's co-authors include Fumie Imabayashi, Hidetoshi Sumimoto, Yutaka Kawakami, Hing Y. Leung, Imran Ahmad, Robert F. Hevner, João Pedro Ferreira, Faı̈ez Zannad, Gerasimos Filippatos and Milton Packer and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and The Journal of Experimental Medicine.

In The Last Decade

Tomoko Iwata

57 papers receiving 2.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

The BRAF–MAPK signaling pathway is essential for cancer-immune evasion in human melanoma cells

2006 528 citations Tomoko Iwata et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Tomoko Iwata United Kingdom	29	1.4k	466	455	377	321	57	2.5k
Saptarsi M. Haldar United States	30	2.3k 1.6×	379 0.8×	669 1.5×	213 0.6×	293 0.9×	54	3.6k
Iván P. Uray United States	20	1.3k 0.9×	434 0.9×	475 1.0×	132 0.4×	160 0.5×	40	2.3k
Nicola Perrotti Italy	30	1.4k 1.0×	228 0.5×	202 0.4×	592 1.6×	175 0.5×	92	2.4k
Narin Osman Australia	36	1.7k 1.2×	313 0.7×	364 0.8×	269 0.7×	842 2.6×	90	3.5k
Chandi Griffin United States	26	1.3k 0.9×	265 0.6×	951 2.1×	717 1.9×	113 0.4×	48	2.6k
Yasuhiro Mitsuuchi United States	24	1.9k 1.3×	427 0.9×	111 0.2×	613 1.6×	488 1.5×	37	2.9k
Fumi Takahashi‐Yanaga Japan	32	2.1k 1.4×	639 1.4×	806 1.8×	113 0.3×	195 0.6×	89	3.3k
Michał Bieńkowski Poland	24	1.2k 0.8×	322 0.7×	121 0.3×	293 0.8×	271 0.8×	80	2.3k
Jingyi Gong United States	20	1.0k 0.7×	451 1.0×	443 1.0×	122 0.3×	137 0.4×	35	2.3k
Laurent O. Martinez France	28	1.6k 1.1×	628 1.3×	289 0.6×	411 1.1×	570 1.8×	81	3.2k

Countries citing papers authored by Tomoko Iwata

Since Specialization

Citations

This map shows the geographic impact of Tomoko Iwata's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tomoko Iwata with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tomoko Iwata more than expected).

Fields of papers citing papers by Tomoko Iwata

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tomoko Iwata. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tomoko Iwata. The network helps show where Tomoko Iwata may publish in the future.

Co-authorship network of co-authors of Tomoko Iwata

This figure shows the co-authorship network connecting the top 25 collaborators of Tomoko Iwata. A scholar is included among the top collaborators of Tomoko Iwata based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tomoko Iwata. Tomoko Iwata is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Carson, Peter, John R. Teerlink, Michel Komajda, et al.. (2025). Comparison of Investigator-Reported and Centrally Adjudicated Heart Failure Outcomes in the EMPEROR-Preserved Trial. JACC Heart Failure. 13(5). 710–721. 1 indexed citations

Butler, Javed, Milton Packer, Tariq Jamal Siddiqi, et al.. (2023). Efficacy of Empagliflozin in Patients With Heart Failure Across Kidney Risk Categories. Journal of the American College of Cardiology. 81(19). 1902–1914. 20 indexed citations

Filippatos, Gerasimos, Dimitrios Farmakis, Javed Butler, et al.. (2023). Empagliflozin in Heart Failure with Preserved Ejection Fraction with and without Atrial Fibrillation. European Journal of Heart Failure. 25(7). 970–977. 19 indexed citations

Siddiqi, Tariq Jamal, Stefan D. Anker, Gerasimos Filippatos, et al.. (2023). Health Status Across Major Subgroups of Patients with Heart Failure and Preserved Ejection Fraction. European Journal of Heart Failure. 25(9). 1623–1631. 10 indexed citations

Böhm, Michael, Javed Butler, Gerasimos Filippatos, et al.. (2022). Empagliflozin Improves Outcomes in Patients With Heart Failure and Preserved Ejection Fraction Irrespective of Age. Journal of the American College of Cardiology. 80(1). 1–18. 39 indexed citations

Filippatos, Gerasimos, Stefan D. Anker, Javed Butler, et al.. (2022). Effects of empagliflozin on cardiovascular and renal outcomes in heart failure with reduced ejection fraction according to age: a secondary analysis of EMPEROR‐Reduced. European Journal of Heart Failure. 24(12). 2297–2304. 29 indexed citations

Pocock, Stuart, João Pedro Ferreira, John Gregson, et al.. (2021). Novel biomarker-driven prognostic models to predict morbidity and mortality in chronic heart failure: the EMPEROR-Reduced trial. European Heart Journal. 42(43). 4455–4464. 32 indexed citations

Packer, Milton, Stefan D. Anker, Javed Butler, et al.. (2021). Empagliflozin in Patients With Heart Failure, Reduced Ejection Fraction, and Volume Overload. Journal of the American College of Cardiology. 77(11). 1381–1392. 107 indexed citations

Tada, Rui, et al.. (2017). Attachment of class B CpG ODN onto DOTAP/DC-chol liposome in nasal vaccine formulations augments antigen-specific immune responses in mice. BMC Research Notes. 10(1). 68–68. 32 indexed citations

10.

Murakami, Hiroya, Tomoko Iwata, Yukihiro Esaka, et al.. (2015). Simple Pretreatment and HILIC Separation for LC-ESI-MS/MS Determination of Adenosine in Human Plasma. Analytical Sciences. 31(11). 1189–1192. 7 indexed citations

11.

Tada, Rui, Saeko Takahashi, Tomoko Iwata, et al.. (2015). Intranasal Immunization with DOTAP Cationic Liposomes Combined with DC-Cholesterol Induces Potent Antigen-Specific Mucosal and Systemic Immune Responses in Mice. PLoS ONE. 10(10). e0139785–e0139785. 53 indexed citations

12.

Ahmad, Imran, Tomoko Iwata, & Hing Y. Leung. (2012). Mechanisms of FGFR-mediated carcinogenesis. Biochimica et Biophysica Acta (BBA) - Molecular Cell Research. 1823(4). 850–860. 158 indexed citations

13.

Thomson, Rachel E., Peter C. Kind, Nicholas Graham, et al.. (2009). Fgf receptor 3 activation promotes selective growth and expansion of occipitotemporal cortex. Neural Development. 4(1). 4–4. 52 indexed citations

14.

Iwata, Tomoko & Robert F. Hevner. (2009). Fibroblast growth factor signaling in development of the cerebral cortex. Development Growth & Differentiation. 51(3). 299–323. 89 indexed citations

15.

Broadgate, Suzanne, Rachel E. Thomson, Francesca Pellicano, et al.. (2005). FGFR3 regulates brain size by controlling progenitor cell proliferation and apoptosis during embryonic development. Developmental Biology. 279(1). 73–85. 66 indexed citations

16.

Pellicano, Francesca, et al.. (2005). Expression of coiled-coil protein 1, a novel gene downstream of FGF2, in the developing brain. Gene Expression Patterns. 6(3). 285–293. 4 indexed citations

17.

Yamamoto, Kohji, et al.. (1998). Increase of plasma brain natriuretic peptide precedes the cardiac remodelling in primary eldery hypertensives. Journal of the American College of Cardiology. 31. 343–343. 1 indexed citations

18.

Iwata, Tomoko, Alexander Kraev, Danilo Guerini, & Ernesto Carafoli. (1996). A New Splicing Variant in the Frog Heart Sarcolemmal Na‐Ca Exchanger Creates a Putative ATP‐Binding Site^a. Annals of the New York Academy of Sciences. 779(1). 37–45. 20 indexed citations

19.

Heim, Roger, Martin J. Hug, Tomoko Iwata, Emanuel E. Strehler, & Ernesto Carafoli. (1992). Microdiversity of human‐plasma‐membrane calcium‐pump isoform 2 generated by alternative RNA splicing in the N‐terminal coding region. European Journal of Biochemistry. 205(1). 333–340. 53 indexed citations

20.

Iwata, Tomoko, et al.. (1991). Bifunctional Atrial Natriuretic Peptide Receptor (Type A) Exists as a Disulfide-Linked Tetramer in Plasma Membranes of Bovine Adrenal Cortex1. The Journal of Biochemistry. 110(1). 35–39. 54 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact